Search

Your search keyword '"Bensinger W"' showing total 12 results
Start Over Author "Bensinger W" Publisher american society of hematology
12 results on '"Bensinger W"'

1. Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

Author

Siegel, David S., primary, Krishnan, A., additional, Lonial, S., additional, Chatta, G., additional, Alsina, M., additional, Jagannath, S., additional, Richardson, P., additional, Hohl, R.J., additional, Lust, J.A., additional, Bensinger, W., additional, Carrum, G., additional, Moreb, J., additional, Simic, A., additional, Barlogie, B., additional, Maziarz, R.T., additional, Anderson, K.C., additional, Lin, J., additional, Lowe, A., additional, Vetticaden, S., additional, and Zhu, J., additional

Published
2006
Full Text
View/download PDF

8. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter]

Author

Storb, R, primary, Pepe, M, additional, Deeg, HJ, additional, Anasetti, C, additional, Appelbaum, FR, additional, Bensinger, W, additional, Buckner, CD, additional, Cliff, RA, additional, Doney, K, additional, and Hansen, J, additional

Published
1992
Full Text
View/download PDF

12. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

Author

S. Vincent Rajkumar, Ruben Niesvizky, Antonio Palumbo, Philippe Moreau, David H. Vesole, Nicolaus Kroeger, P. Leif Bergsagel, Pieter Sonneveld, Joan Bladé, Mario Boccadoro, Brian G.M. Durie, Hans Erik Johnsen, Jesús F. San Miguel, Gösta Gahrton, Michele Cavo, Paul G. Richardson, Kenneth C. Anderson, Heinz Ludwig, Meletios A. Dimopoulos, Sagar Lonial, Sundar Jagannath, Robert Z. Orlowski, O. Sezer, Michel Attal, Hermann Einsele, William I. Bensinger, Radiology & Nuclear Medicine, Hematology, Cavo M., Rajkumar S.V., Palumbo A., Moreau P., Orlowski R., Bladé J., Sezer O., Ludwig H., Dimopoulos M.A., Attal M., Sonneveld P., Boccadoro M., Anderson K.C., Richardson P.G., Bensinger W., Johnsen H.E., Kroeger N., Gahrton G., Bergsagel P.L., Vesole D.H., Einsele H., Jagannath S., Niesvizky R., Durie B.G., San Miguel J., and Lonial S.

Subjects
Oncology, medicine.medical_specialty, autologous stem cell transplantation, Immunology, Biochemistry, Transplantation, Autologous, Disease-Free Survival, Autologous stem-cell transplantation, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Survival rate, Multiple myeloma, Lenalidomide, business.industry, Bortezomib, Age Factors, International Myeloma Working Group, Cell Biology, Hematology, medicine.disease, Surgery, Transplantation, Thalidomide, Survival Rate, Proteasome inhibitor, business, Multiple Myeloma, medicine.drug, Perspectives, Stem Cell Transplantation
Abstract

12 páginas, 3 tablas.-- et al., The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results